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Loss of the long arm of chromosome 6 (6q) has frequently been reported in gastric 
carcinoma, suggesting a loss of function of putative tumor suppressor gene(s) within this 
region. 
Materials & Methods 
In order to have an overview of the genomic imbalances in gastric carcinomas, especially 
for an impression of the frequency of chromosome 6 aberrations, ten tumors were studied 
with the comparative genomic hybridization (CGH) technique. To more precisely define 
the critical deletion region of chromosome 6q, we also have constructed a high-resolution 
deletion map on the long arm of chromosome 6q in twenty-five cases of gastric 
carcinomas. Seventeen microsatellite markers were used to detect loss of heterozygosity 
(LOH) in microdissected tumor. Intestinal metaplasia foci, where present, of the stomach 
in the same cancer patient were also examined for the locus in which L O H was seen in 
the tumor. 
Results 
Loss of chromosome 6q was observed in 4 of 10 cases (40%) of gastric carcinomas by 
CGH. High frequencies, 72% of cases, of L O H on chromosome 6q were detected in our 
samples. Two distinct regions of common allelic loss were identified: Region A, a 18cM 
region on 6ql4-21, bordered by markers D6S286 and D6S468 with L O H frequency of 
26.1% (6/23), and Region B, a 19.7cM region on 6q27, bordered by markers D6S297 and 
D6S281 with L O H frequency of 41.7% (10/24). One case exhibited microsatellite 
i 
instability at multiple loci. L O H at locus D6S446 was observed in tumors but not in the 
intestinal metaplasia of the same stomach. 
Conclusions 
W e conclude from these data that genomic losses involving 6q is a frequent event in 
gastric carcinoma and probably contributes to its pathogenesis. The deletions fall into two 
discrete regions, suggesting the existence of at least two tumor suppressor genes in 6q. 
Loss of 6q is not seen in intestinal metaplasia but found in gastric carcinomas of all 
stages, including early cancers. W e propose that the genetic losses occur after the 
precancerous phase of intestinal metaplasia and may be a critical event in the final 
establishment of bona fide cancer. This is the first study to demonstrate the temporal 
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I. INTRODUCTION 
I.l Gastric Carcinoma 
Although decreasing in incidence, gastric cancer is the second most common cause of 
cancer-related deaths in the world (Globocan 2000, lARC). The majority of gastric 
carcinomas are detected at an advanced stage. The prognosis for gastric cancer is 
therefore very poor, with 5-year survival rates less than 20% (Breaux et al 1990). Gastric 
carcinomas usually occur in patients older than 50 years of age; only about 5% are 
younger than 40 years (Neugut et al 1996). This cancer is not uniformly distributed 
throughout the world's populations. There are geographical variations both among and 
within countries. High incidence rates were reported in Japan, China, Chile，Portugal, 
Costa Rica, Italy, Colombia, and considerably lower in the France, Philippines, Denmark, 
Canada, Australia, India，Pakistan and Cuba (Neugut et al 1996). 
In Hong Kong, gastric cancer is the fourth leading cause of death in 1998. The incidence 
of gastric carcinoma has been reported to be 6.5 per 100,000 population 
(http://www.who.whosis.int). Male have getting higher chance of developing gastric 
carcinoma than female. Furthermore, despite of various advances in technology, this 
tumor is still diagnosed at an advanced stage and thus has a poor survival rate (Neugut et 
al 1996). Therefore, gastric carcinoma still remains a significant contributor to the Hong 
Kong's health's burden. 
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1.2 Etiology of Gastric Carcinoma 
The etiology of gastric adenocarcinoma has been extensively investigated. The major risk 
factors thought to cause gastric carcinoma are summarized in table 1. 
L2,l Environmental Factors: 
Consumption of salted and nitrated food is believed to be primarily responsible for the 
high incidence and mortality rate of gastric carcinoma (Watenabe et al 1997). High 
intakes of salt can cause stomach irritation, which may induce atrophic gastritis and make 
gastric mucosa more susceptible to the development of carcinoma. Salt also causes 
excessive cell replication and increases the mutagenicity of nitrosalted foods. When 
nitrate undergo nitrosation, heavily nitrate food may induce the synthesis of carcinogen, 
N. Nitro compounds (NOC) which have been shown to induce gastric tumors in animals 
(Mirvish et al 1983). On the other hands, intakes of green-leaf vegetables and fruits, 
especially citrus fruit, which contain anti-oxidant are associated a lower risk of gastric 
carcinoma. 
1.2,2 Helicobactor Pylori Infection: 
Helicobactor pylori (H. pylori) have been reported in most cases of intestinal type of 
gastric carcinoma (Tahara et al 1994). In 1994，it was classified as a Group 1 carcinogen 
by the International Agency for Research on Cancer (lARC) and World Health 
Organization (WHO), suggesting that there is sufficient epidemiologic evidence in 
humans for the carcinogenicity of infection with H. pylori (lARC 1994, Eurogast 1993). 
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Infection of stomach with H. pylori leads to gastric inflammation. It is believed that 
chronic infection with H. pylori leads to alterations of the cell cycle, including increased 
epithelial cell replication, increased rate of apoptosis and production of oxidants. 
Together with depletion of anti-oxidant defenses, this may predispose to carcinogenesis 
by increasing the likelihood ofDNA mutagenesis (Stadtlander et al 1999). Subsequently, 
the accumulation of mutations may lead to gastric metaplasia, dysplasia and cancer 
(Stadtlander et al 1999, Correa et al 1992). 
Furthermore, Leung et al reported all gastric carcinoma and intestinal metaplasia samples 
with microsatellite instability had evidence of active H. pylori infection in the stomach 
(Leung et al 2000). Therefore, they speculated that chronic H. pylori infection might 
accelerate the accumulation of genetic alterations in gastric mucosa that would be carried 
onto gastric metaplasia and finally progress to cancer. Further studies might be useful for 
defining the etiologic role of H. pylori in inducing gastric carcinoma. 
L2.3 Genetic Factors: 
Previous study has suggested that gastric carcinoma occurs more frequently among close 
relatives of affected patients than general population (La Vecchia et al 1992). Blood 
typing studies suggest that group A people are more frequently associated with gastric 
carcinoma than other blood groups (Stadtlander et al 1999). 
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1,2.4 Other Factors: 
Several studies have shown that smokers have a higher frequency of suffering gastric 
carcinoma, although most studies have failed to demonstrate a clear dose response 
relationship (Fuchs et al 1995). Other studies have also suggested cigarette smoking may 
increase the incidence of pre-malignant lesions, however a clear relationship has not been 
demonstrated (Fuchs et al 1995). Similarly, the relationship between alcohol 
consumption and the risk of gastric carcinoma is inconclusive. 
Risk factors for gastric carcinoma 
(1) Environmental factors: 
Salted and nitrated foods 
(2) Helicobactor Pylori infection 
(3) Genetic factors: 
Family history and 
Blood group A 
(4) Other factors: 
Cigarette smoking and 
Alcohol consumption 
Table 1. Risk factors for gastric carcinoma. 
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1.3 The Lauren Classification of Gastric carcinoma 
The classification developed by Lauren, in 1965 (Lauren et al 1965), has been widely 
used because it describes two biological entities that are different in epidemiology, 
etiology, pathogenesis and behavior. It distinguishes gastric carcinoma into two major 
types, intestinal and diffuse. 
Gross appearance of gastric carcinoma is shown in figure 1. 
The histopathology of these tumors is described below: 
L3.1 Histolopathology of Intestinal Type of Gastric Carcinoma 
The intestinal type of gastric carcinoma is composed of large and irregular nuclei in large 
and distinct cells. These cells retain sufficient cell cohesion allowing the formation of 
gland-like tubular structure (Figure 2). The neoplastic cells often contain acid mucin 
vacuoles. Abundant mucin may be present in glandular lumens. It is a better-
differentiated neoplasm. This neoplasm is usually associated with intestinal metaplasia 
(Figure 3), therefore it has been suggested that intestinal metaplasia is a precancerous 
lesion of intestinal type of gastric carcinoma (Semba et al 1996). 
Clinical-epidemiological studies reported that intestinal type of gastric carcinoma is 
commonly found in countries with high incidence rates, such as Japan and Korea, and 
appeared to be more common in males and in the elderly (Neugut et al 1996). 
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Figure 2: H & E staining of intestinal type of gastric carcinoma. It composed of malignant 
cells forming neoplastic intestinal glands. 
Figure 3. H&E staining of intestinal metaplasia. Intestinal metaplasia is characterized by 
the present of goblet cells. H.pylori infection is noted. 
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L3,2 Histopathology of Diffuse Type of Gastric Carcinoma 
The diffuse type is composed of gastric type mucous cells, which generally do not form 
glands as in intestinal type. The neoplastic cells are scattered or in small clusters which 
are arranged in a non-polarized pattern (Figure 4). In this variant, mucin formation 
expands the malignant cells and pushes the nucleus against the cell membrane, creating a 
“signet ring” conformation. The amount of mucin formation varies. There may be 
absence of mucin in a poorly differentiated portion of the tumor. This type of carcinoma 
is tend to metastasize and generally shows a more aggressive clinical course. 
The incidence of diffuse type of gastric carcinoma appeared similarly high in most 
population, with equal sex ratio and occurring at younger age (Neugut et al 1996). 
8 
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Figure 4: H & E staining of diffuse type of gastric carcinoma. It composed of 
scattered signet ring cells in the mucosa. 
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1.4 Cytogenetics Studies in Gastric Carcinoma 
L4,l Cytogenetic Studies of Gastric carcinoma 
1.4.1.1 Conventional Cytogenetic Studies of Gastric Carcinoma 
Conventional cytogenetic studies of gastric carcinoma have reported complex karyotypes, 
with multiple numerical and/or structural abnormalities (Panani et al 1995, Seruca et al 
1993, Tzeng et al 1991，Ferti-Passantonpoulou et al 1987, Ochi et al 1986). 
Ochi et al found that loss of chromosome Y was the most prominent karyotypic in gastric 
tumors (Ochi et al 1986). Structural abnormalities involving breaks at lp22, 3p21 and 
19pl3 were observed. This group also observed an extra copy of chromosome 12. Ferti-
Passantonopoulou et al studied five cases of gastric carcinoma and observed the most 
common structural abnormalities involved chromosome 9，and extra copies of 
chromosomes 7, 8 and 9 (Ferti-Passantonopoulou et al 1987). In a study of eleven gastric 
carcinomas, Seruca et al reported frequent structural aberrations involving chromosomes 
1,3,6,7,11 and 13 with polysomy of chromosomes 2 and 20 (Seruca et al 1993). Panani et 
al studied eleven cases of gastric tumors and reported frequent structural abnormalities of 
chromosome 3, 6 and 13，along with extra copies of chromosome 8 (Panani et al 1995). 
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Three studies have reported structural abnormalities in chromosome 6. Seruca et al found 
loss of chromosomal segment distal to band 6q21-22 in 5 of 11 cases (45%) (Seruca et al 
1993). Deletion of this region was also reported by Ochi et al and Panani et al (Ochi et al 
1986, Panani et al 1996). Genetic changes at 6q have been reported in other solid tumors, 
including carcinoma of breast and hematological malignancies. Thus it has been 
suggested that these affected regions may contain one or more tumor suppressor genes 
that is inactivated during the neoplastic process. 
The summary of cytogenetic studies is shown in Table 2. 
Deletions^ Addition of Re-arrangement References 
chromosomes chromosomes of chromosomes 
1 Y, 6q 12 Ip, 3p, 19p Ochi et al 1986 
2 7,8 9 Ferti-Passantonopoulou et 
al 1987 
1 8,9, 12 5,8, 11’ 14 Tzeng et al 1991 
"4 ^ 1,3,7, 13 Seruca et al 1993 
"5 3q, 5,6q 8, 17p 12, 13 Panani et al 1995 
Table 2. Summary of conventional cytogenetics studies on gastric carcinomas. Note loss 
of 6q was frequently found. 
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1.4.1.2 Comparative Genomic hybridization (CGH) 
C G H is a recently developed cytogenetic technique. It allows the detection of genetic 
imbalance in a single experiment. So far, there were only eleven studies on gastric 
carcinoma using CGH. The most common chromosomal gains were located on 
chromosome 8q, 17q, 20p and 20q while chromosomal losses on 4p, 4q, 5q, 17p and 18q. 
(Kim et al 2001, W u et al 2001, Guan et al 2000, Koo et al 2000, Okada et al 2000, Van 
Grieken et al 2000, Nakanishi et al 2000，Sakakaura et al 1999, Nessling et al 1998， 
Koizumi et al 1997, Kokkola et al 1997). Higher frequencies of gains and losses were 
detected in cell line (Okada et al 2000). Asian population seems to have more complex 
genetic aberrations than Caucasian. It might be due to geographic variations for gastric 
carcinoma. 
















































































































































































































































































































































































































































































































































































































































































































1.5 Molecular Studies of Gastric Carcinoma 
Molecular genetic studies have provided evidence that genetic alterations play an 
important role in the multistage process of carcinogenesis and tumor progression. Genetic 
instability, activation of oncogenes, inactivation of tumor suppressor genes and loss of 
chromosomes carrying tumor suppressor genes are the key events for the tumorogenesis 
of gastric carcinoma. 
L 5.1 Genetic Instability 
Genetic instability is being recognized as one of the earliest changes in carcinogenesis 
(Chan et al 1999). Chong et al detected microsatellite instability (MSI) in 33% of well-
differentiated gastric carcinoma and in 18% of the poorly differentiated carcinoma 
(chong et al 1994). On the other hand, Dos Santos et al and Rhyu et al observed MSI in 
32% and 34%, respectively (Dos Santos et al 1996, Rhyu et al 1994). The frequency of 
MSI has also been reported to be lower in early gastric carcinoma than in advanced 
gastric carcinoma (Tamura et al 1996, Tamura et al 1995). Kobayashi et al reported 
microsatellite instability was relatively common in intestinal metaplasia and all MSI 
observed in intestinal metaplasia was also observed in cancerous tissues (Kobayashi et al 
2000). This finding suggested that genetic instability in intestinal metaplasia may lead to 
early gastric carcinoma (Kobayashi et al 2000). 
14 
Moreover, Leung et al demonstrated a high frequency of MSI in gastric intestinal 
metaplasia from patients with and without gastric carcinoma (Leung et al 2000). These 
data suggested that progressive accumulation of MSI of intestinal metaplasia may 
contribute to gastric carcinogenesis, representing an important molecular event in the 
multistep gastric carcinogenesis cascade. 
In addition to MSI, reduction in telomere length may lead to chromosomal instability, 
additional genetic alterations, reactivation of telomerase and ultimately progress to 
cancer. Gastric intestinal metaplasia and gastric carcinoma displayed shorter telomere 
length than in normal gastric mucosa (Tahara et al 1994). A good correlation was found 
between telomere length reduction and tumor staging in primary tumor of gastric cancer. 
7.5.2 Amplification/ Mutation of Oncogenes 
Amplification of genes has been reported in gastric carcinoma. Gene amplification results 
in increased copy number of genes, and in many cases it is usually associated with 
increased gene expression. It addition to gene amplification, oncogene activation can 
occur by mutations or structural rearrangement. 
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1.5.2.1 The ras Gene 
The mutation of ras gene is relatively infrequent in gastric carcinoma. Nevertheless, 
enhanced expression of the ras genes have been reported in gastric carcinoma (Chan et al 
1999). A higher rate of enhanced expression of ras was found in intestinal type than in 
diffuse type of gastric carcinoma, and in advanced than in early gastric carcinoma (Chan 
et al 1999). 
Gastric cancer cell lines containing mutated ras alleles have been described. Deng and his 
fellows reported mutation in the codon of H-ras in 5 of 18 gastric cancers (Deng et al 
1991). This study also suggested an association between ras mutations, the presence of 
distant metastases and shorter survival. However, other studies found low frequency of 
ras mutation in gastric cancer (Endoh et al 2000, Nanus et al 1990, Victor et al 1990). 
Overall, studies with primary gastric cancer suggested that the incidence of ras mutation 
is less than 7%. 
1.5.2.2 The c-erbB-2 Gene 
The c-erbB-2 gene is a member of the epidermal growth factor (EGF) receptor family and 
was found to encode trans-membrane glycoprotein of the tyrosine kinase family. This 
gene is located on chromosome 17q21. 
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Amplification of c-erbB-2 gene has been reported mostly in the intestinal type and 
advanced gastric carcinoma (Wu et al 1997). Yokota and his fellows reported high 
frequency of c-erbB-2 gene amplification (40%) in intestinal type of gastric carcinoma, 
but none in diffuse type (Yokota et al 1988). Overall, amplification of c-erbB-2 gene has 
been reported to range from 10.4% to 11% (Nakajima et al 1999, Ishikawa et al 1997). 
Previous reports suggested that over-expression of c-erhB2 gene was significantly more 
frequent in intestinal type than in diffuse type and in advanced carcinoma than in early 
gastric cancer (Mizutani et al 1993). Similar results were also observed by Ishikawa and 
his fellows (Ishikawa et al 1997). Moreover, gene amplification and over-expression of c-
erhB2 correlated with poor survival rate for gastric carcinoma patients (Nakajima et al 
1999, Mizutani et al 1993). Interestingly, a good correlation is observed between 
overexpression of c-erbB-2 and liver metastasis, indicating that it is a good marker for 
liver metastasis of gastric carcinoma (Mizutanzi et al 1993). 
1.5.2.3 The c-met Gene 
The c-met gene was originally identified as a transforming gene of a human osteogeneic 
sarcoma cell line (HOS) transformed with N-methyl-N'-nitro-N-nitrosoguanidine 
(MNNG)(Wang et al 1995). This proto-oncogene encodes a growth factor receptor 
controlling cell proliferation of epithelial cells of the liver and of the gastrointestinal tract 
(Prat et al 1991). This gene is located on chromosome 7q31 (Giordano et al 1989). 
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Amplification of c-met gene has been reported frequently in gastric carcinoma, especially 
the diffuse type (Nakajima et al 1999, W u et al 1997, Kuniyasu et al 1992). They also 
reported that abnormal transcript of 60 kb c-met gene was closely associated with lymph 
node metastasis and depth of tumor invasion (Kuniyasu et al 1993). Furthermore, it was 
expressed in gastric cell lines as well as in cancer tissues but not in non-neoplastic 
mucosa. Southern blot analysis of xenografts of gastric tumors detected 18-fold 
amplification of c-met (Seruca et al 1995). Moreover, Nakajima and his collages reported 
c-met amplification and over-expression is closely related with advanced tumor stage and 
poor prognosis (Nakajima et al 1999). 
1.5.2.4 The k-sam Gene 
This gene was originally isolated from a gastric cancer cell line (KATO-III) (Hattori et al 
1996, Nakatani et al 1990). It is a member of the fibroblast growth factor (FGF) receptor 
family and a variant of FGFR-2. This gene is located on chromosome 10q25 (Ochiai et al 
1997). 
The amplification of k-sam gene has been reported in 21% of diffuse type of gastric 
carcinoma, but rare in intestinal type (Hattori et al 1990). The authors also reported that 
amplification of k-sam was usually found in advanced stage of gastric carcinoma, and 
some cases only in metastatic foci. Therefore, amplification of k-sam gene is suggested to 
occur in a late event during carcinogenesis of diffuse type of gastric carcinoma. 
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1.5.2.5 The c-myc Gene 
The c-myc gene is located on chromosome 8q24. It encodes a nuclear transcriptional 
factor that may play a role in transcription and cell cycle control. 
Amplification of c-myc gene has rarely been found in gastric cancer (Ranzani et al 1990), 
but detected in some studies (Ciclitira et al 1987, Nakasato et al 1984). Seruca and his 
colleges detected 8-fold, 7-fold and 5-fold amplification level of c-myc in xenografts of 
gastric tumors, metastatic tumors and primary gastric tumors respectively (Seruca et al 
1995). Over-expression of c-myc protein has also been reported to correlate with the stage 
of gastric carcinoma (Yamamoto et al 1987). 
1.5.2.6 The hst-l/hst-2 Gene 
The hst-1 gene was originally identified by transfection assays utilizing NIH-3T3 cells. It 
encodes a member of the FGF family (Wang et al 1995). Hst-1 gene is located on 
chromosome 1 lql3 and hst-2 is located adjacent to hst-1. 
Co-amplification of hst-1 and hst-2 has been reported in gastric carcinoma (Tsujino et al 
1990). However, previous studies have indicated that it is infrequently amplified or over-
expressed in gastric carcinoma (Houldsworth et al 1990, Tsuda et al 1989). 
Overall, proto-oncogene amplification in gastric carcinoma is a relatively infrequent 
phenomenon, but it is usually associated with advanced or metastatic tumors (Wang et al 
1995). 
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L5.3 Alterations of Tumor Suppressor Genes 
Loss of heterozygosity (LOH) studies have identified a number of chromosomal regions 
that demonstrated allelic imbalance in primary gastric carcinoma. These include 
chromosomes 3p, 5q, 9p, 13q，17p and 18q (Kim et al 2000, Yuestin et al 1999，Choi et 
al 1998，Nishizuka et al 1998, Gleeson et al 1997, Tamura et al 1996，Schneider et al 
1995，Sano et al 1991). L O H occurring frequently at a specific locus is widely assumed 
to imply the presence of a tumor suppressor gene on or near that locus. Lost function of 
these tumor suppressor genes allows cancer to develop. The known tumor suppressor 
genes involved in gastric carcinoma are discussed in more detail below. 
1.5.3.1 The p53 Gene 
p53 is located on chromosome 17pl3 and L O H has been frequently noted in this sites. 
p53 gene, tumor suppressor gene, is the most common mutated gene in human cancers. It 
regulates D N A replication, cell proliferation and cell death. 
L O H and mutation of p53 were observed in 68% of both types of gastric carcinoma 
(Sano et al 1991). This group also found loss of chromosome 17p in gastric adenoma, 
suggested that mutation of p53 take places in early stage of gastric carcinoma. Similar 
results have been observed by Shiao et al, showing p53 alterations in 38% of intestinal 
metaplasia, 58% of dysplasia and 66% of gastric carcinoma (Shiao et al 1994). 
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Uchino and fellows reported mutation of p53 gene in 37% of early gastric cancer and in 
42% of advanced gastric cancer (Uchino et al 1993). Furthermore, a study reported 
frequent p53 abnormalities (57%) in advanced gastric cancer (Martin et al 1992). This 
group also observed that increased p53 expression was associated with poor prognosis. 
Briton et al observed an increased frequency of p53 immunopositivity in the sequence of 
gastric dysplasia, early gastric cancer to advanced gastric cancer, suggesting that the 
abnormalities of p53 related to tumor progression in gastric cancer (Brito et al 1994). 
1.5.3.2 The Adenomatous Polyposis Coli Gene (APC) 
The APC gene is located on chromosome 5q21 and adjacent to Colon Carcinoma gene 
(MCC gene). It plays an important role in cell adhesion, cytoskeletal anchoring, and 
possibly in cell signaling pathways (Kim et al 1999). 
Previous reports revealed that the high incidence of L O H on chromosome 5q was 
observed in 60% of intestinal type, but not in diffuse type of gastric carcinoma (Horii et 
al 1992, Sano et al 1991). The loss of 5q in gastric carcinoma was confirmed in later 
studies that noted a frequency of 30% in twenty gastric carcinomas and 34% in fifty-two 
gastric carcinomas (Cho et al 1996, Rhyu et al 1994). Somatic mutations of the APC 
gene were found in 20% to 42% of gastric adenoma and 6% of intestinal metaplasia of 
stomach (Nishimura et al 1995, Tamura et al 1994). Hence, it was suggested that 
alteration of APC is an early genetic event in gastric carcinogenesis (Tamura et al 1994). 
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1.5.3.3 The Deleted-in-Colon-Cancer Gene {DCC) 
The DCC gene is located on chromosome 18q21. It encodes a cell surface, trans-
membrane protein with considerable homology to neural cell adhesion molecules (Katoh 
etan99?>). 
L O H at DCC gene is detected in 61% of intestinal type gastric carcinoma and suggested 
that it occurs at an earlier stage of gastric cacinogenesis (Uchino et al 1992). In contrast, 
Cho and his colleague found L O H in 30% and 25% of intestinal type and diffuse type of 
gastric cancer respectively (Cho et al 1996). Nevertheless, these studies suggested that 
abnormalities near the DCC gene occur frequently in gastric carcinoma and it may 
promote the development of gastric carcinoma. Mizutani et al suggested that the mutation 
of DCC precedes p53 allelic loss in adenoma-carcinoma sequences in gastric tumors 
(Mizutani et al 1993). 
1.5.3.4 Other Genes: Retinoblastoma Gene {RE) 
The Rb gene is located on chromosome 13ql4. L O H at this locus was observed in 52% of 
gastric cancer (Gleeson et al 1997). However, other studies documented a lower 
incidence of loss of chromosome 13q, ranging from 10 to 30% (Cho et al 1996, Uchino et 
al 1992). Although L O H for chromosome 13q had been reported, previous study reported 
a relative infrequent rate of Rb gene involvement. This suggested that Rb alteration does 
not play a crucial role in the oncogenesis of gastric carcinoma (Constancia et al 1994). 
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L 5.4 Cell Adhesion Molecules 
Cell adhesion molecules may also function as tumor suppressor molecule. Mutation of 
these molecules may cause loss of adhesion of cells, which is a critical of malignancy, 
and thus favor metastasis. 
1.5.4.1 E-cadherin 
Cadherin is involved in numerous cellular functions, including establishing and 
maintaining intercellular connections, controlling cell polarity and morphogenesis 
(Takeichi et al 1991). E-cadherin is located at 16q22-q24. 
The E-cadherin gene is frequently inactivated via the classic two hit mechanism and 
mutations of E-cadherin gene have been reported to occur preferentially in 50% of 
diffuse type of gastric carcinoma, but rarely in intestinal type (Becker et al 1994). In 
addition, frequent inactivation of E-cadherin via hypermethylation of promoter region 
CpG islands has recently been reported for diffuse type gastric carcinoma (Tamura et al 
2001, Tamura et al 2000). Decreased expression of E-cadherin by immunohistochemical 
study has been found in most diffuse type of gastric carcinoma and correlated with 
shorter patient survival after curative surgery regardless of stage of disease (Shino et al 
1995). These observations strongly suggested that gene alterations and reduced 
expression of E-cadherin are involved and play an important role in the development and 
invasion of diffuse type of gastric carcinoma. 
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1.5.4.2 CD44 
CD44 regulates adhesion, movement and activation of normal and non-neoplastic cells. 
Expression of abnormal CD44 transcript was detected in 67% of intestinal type and 90% 
of diffuse type gastric cancers (Yokozaki et al 1994). Different over-expression patterns 
of aberrant CD44 transcript were observed in intestinal metaplasia and gastric carcinomas 
(Higaskawa et al 1996). The authors also suggested that expression of abnormal CD44 
transcripts is presumably a powerful indicator of the presence of gastric carcinoma 
(Higaskawa et al 1996). 
The molecular genetics in gastric carcinogenesis have suggested that the development of 
intestinal and diffuse type gastric carcinoma follows two different pathways. Table 4 
summaries the genetic alterations in both intestinal and gastric types of gastric carcinoma. 
Furthermore, it has been postulated that atrophic gastritis, intestinal metaplasia and 
dysplasia are pre-cancerous stages of stomach tumorogenesis (Chan et al 1999). Figure 5 
illustrates the possible genetic pathways for two types of gastric carcinomas. 
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Lauren's Classification  
Intestinal type Diffuse type (%) 
Genes (alterations) Location  
Genetic Instability 11 40 
Telomerase Activity 100 90 
Activation of Oncogenes 
K-ras (mutation) 10q25 9 -
c-met 8q24 
Amplification 19 39 
6.0kb m R N A 50 82 
K-sam (amplification) - 33 
c-erbB-2 (amplification) 17q21 20 -
hcl-2 (LOH) 43 -
Cyclin E (amplification) 16 10 10 
Tumor Suppressor Genes 
p53 (LOH, mutation) 17pl3 60 76 
APC (LOH, mutation) 5q21 40-60 -
DCC (LOH) 18q21 50 -
Cell Adhesion Molecules 
Cadherin, catenin (deletion) - 50 
CD44 (abnormal transcript) 100 100 
L O H 
Ip 25 38 
Iq 44 -
7q 53 33 
Table 4. Summary of gene alterations in intestinal and diffuse type of gastric carcinoma 
(Table modified from Tahara et al 1995). 
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Figure 5. The diagram illustrates the molecular pathway and the possible role of 
Helicobactor pylori in the development of intestinal and diffuse types of gastric 
carcinoma. (Diagram is adopted from Chan et al 1999). 
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L 5.5 Molecular Studies on Intestinal Metaplasia 
Intestinal metaplasia of the stomach is defined as the replacement of gastric mucosa by 
glands composed of epithelium resembling that of intestinal intestine. Most gastric 
cancer patients have evidence of intestinal metaplasia in the stomach. Not all patients 
with intestinal metaplasia develop cancer, but the risk of gastric carcinoma is 
proportional to the extent of intestinal metaplasia (Stemmermaim et al 1994). 
Furthermore, the genetic alterations frequently observed in gastric carcinoma also have 
been reported in intestinal metaplasia (Fleisher et al 2001, Kang et al 2001, Kobayashi et 
al 2000). However, current knowledge in genetic alteration of this pre-cancerous lesion is 
still superficial and is limited to reports on microsatellite instability, methylation, 
mutations of p53, APC and K-ras genes (Kang et al 2001，Kobayashi et al 2000, Semba 
et al 1996, Nishimura et al 1995). Therefore, previous studies postulated that intestinal 
metaplasia is a pre-cancerous lesion of the stomach cancer (Semba et al 1996). 
L O H of p53 gene was reported in 14% of intestinal metaplasia while in 22% gastric 
carcinoma (Tahara et al 1994). Somatically mutated APC gene was reported in 6% of 1 
intestinal metaplasia and in 42% of gastric carcinoma (Nishimura et al 1995). Later, 
Kobayashi et al observed L O H in 45% of intestinal metaplasia lesion and 73% gastric 
carcinoma (Kobayashi et al 2000). Furthermore, Kang et al reported that there were 
increased methylated genes from intestinal metaplasia to gastric carcinoma (Kang et al 
2001). These findings suggested that a portion of intestinal metaplasia may have 
epigenetic change or genetic alterations and act as a precancerous lesion of gastric 
carcinoma. 
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II. LONG ARM OF CHROMOSOME 6 
Structural abnormalities of chromosome 6, resulting in loss of the chromosomal segment 
distal to band 6q21-22, were reported frequently in conventional cytogenetic studies of 
gastric carcinoma (Panani et al 1995, Seruca et al 1993, Ochi et al 1986) (Table 2). 
There is a large variance in reporting the frequencies of 6q loss by CGH, ranging from 
0% to 60% (Table 3). Okada et al observed loss of 6q21-26 in cell lines HSC-39, HSC-
40A and MNK-45 (Okada et al 2000). Sakakura et al and W u et al detected loss of 6q in 
26% of gastric carcinoma (Wu et al 2001，Sakakura et al 1999). In contrast, Koizumi et 
al observed increases in copy number of 6q23-25 in six out of thirty-three cases (18%) of 
gastric carcinomas, but detected loss in cell line K A T O III at 6ql6-q21 (Koizumi et al 
1997). Moreover, low frequencies of loss of 6q have been reported by other studies (Kim 
et al 2001, Nakanishi et al 2000, Guan et al 2000, Van Grieken et al 2000, Koo et al 
2000, Nessling et al 1998, Kokkola et al 1997). 
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Moreover, in previous allelotyping studies on whole chromosomes of gastric carcinoma, 
high frequency (25 to 53%) of loss of heterozygosity has been detected on 6q (Gleeson et 
al 1997, Schnedider et al 1995, Seruca et al 1995) (Table 5). In particular, Gleeson and 
his fellows detected allelic loss of chromosome 6 in 78% and 48% of diffuse type and 
intestinal type of gastric carcinomas, respectively (Gleeson et al 1997). Loss of 
chromosome 6q was also detected in 25% of gastric cell lines and 29% of primary gastric 
adenocarcinoma by allelotyping (Yustein et al 1999, Schneider et al 1995). In contrast, 
Sano et al failed to detect any loss of chromosome 6 (Sano et al 1991). Only one marker 
was used in his study may explain the difference. As some benign and borderline tumors 
were included in Kim's study, lower frequencies of L O H on 6q were observed (Kim et al 
2000). 
Recently, Queimado et al identified two separate regions of overlapped deletions at 6q in 
gastric carcinoma, one between 6ql6.3-q21 and 6q22.3-q23.1 (SROl), another distal to 
6q23-q24 (SR02) by L O H (Queimado et al 1995). These studies have suggested the 
existence of one or more putative tumor suppressor genes on chromosome 6q that is 
involved in the pathogenesis of gastric carcinoma. Later, same group of people using 
more microsatellite markers further delimited the 12-16cM SROl in 6ql6.3-q23 to a 
region of 2cM (Carvalho et al 1999). 
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3p 59.5 81 36 
3q 
4p 21 64 
4q 73 
5p 
5q 50 33 17 58 69 
6p 37 
6q 0 0 8 52.6 25 29 7 
7p 
7q 43 39 19 
8p 57.6 57 
8q 
9p 14.3 68 64 36.4 
9q 14.3 71.5 
10q 
11q 36 26 31 
12q 58 38 
13q 52.6 59 33 38.1 
14p 64.2 





17p 39 37.5 83 80 74 48 
17q 32 
18p 




21q 40 43 
22q ^  
Table 5. Summary of Loss of Heterozygosity studies on gastric 
carcinoma. High frequency (25% to 53%) of loss of heterozygosity 
has been detected on 6q (Gleeson et al 1997, Schnedider et al 
1995, Seruca et al 1995). 
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Previous studies in different tumors had detected chromosomal deletions on the long arm 
of chromosome 6 including acute lymphocytic leukemia (Jackson et al 2000)，B cell non-
Hodgkin lymphoma (Merup et al 1998), mesothelioma (Bell et al 1997), malignant 
melanoma (Miele et al 2000), natural killer cell lymphoma (Siu et al 2000)，pancreatic 
cancer (Abe et al 1999), carcinoma of cervix (Chuaqui et al 2001), gall bladder (Wistuba 
et al 2001), liver (Koyama et al 2000), lung (Virmani et al 1998)，ovary (Cooke et al 
1996，Saito et al 1992)，prostate (Srikantan et al 1999), papillary serous carcinoma of the 
peritoneum (Huang et al 2000) and breast (Utada et al 2000, Chappell et al 1997) as well 
as adenomas of the parathyroid gland (Tahara et al 1996) (Figure 6). The incidence of 6q 
deletions ranged from 30 to 80%, further suggesting the existence of putative tumor 
suppressor genes specific to several types of human cancers on 6q. 
Moreover, the tumor suppressor genes activity of chromosome 6 has been established by 
microcell-mediated chromosome transfer studies, it indicated that introduction of a 
normal chromosome 6 can reverse the tumorigenic phenotype of a tumor cell line of 
melanoma, uterine endometrial carcinoma and mammary carcinoma (Negrini et al 1994， 









































































































































































































































































































































































































































































































































































































































































































































III. BRIEF REVIEWS OF THE TECHNIQUES USED 
IN THIS STUDY 
III.l Comparative Genomic Hybridization (CGH) 
C G H is a newly developed molecular cytogenetic method that allows the entire genome 
to be analyzed for gains and loss in the D N A copy number in a single experiment 
(Kallioniemi et al 1994，Kallioniemi et al 1992). In contrast to banding analysis, C G H 
does not required preparation of metaphase chromosomes from the cells to be analyzed. 
The principle of C G H is shown in figure 7. C G H is based on the simultaneous 
hybridization of differentially labeled tumor and normal D N A to normal metaphase 
chromosome. The test D N A is labeled with biotin. Genomic D N A derived from cell with 
a normal karyotype is labeled with digoxigenin and serves as an internal control. For the 
detection of the hybrided test and control DNA, fluorescein isothiocyanate and anti-
digoxigenin rhodamine were used respectively. If the test D N A harbors additional 
chromosomal material (such as a trisomy, and amplification etc), higher signal intensities 
at the corresponding target regions can be detected. Correspondingly, deletions in the test 
sample are visible as lower signal intensities. By comparing the fluorescence intensities 
of the test and control DNA, changes in fluorescence signal intensities caused by 
imbalances of the test D N A can be quantified. Chromosomal regions were interpreted as 
over-represented (gain) when the profile ratio exceeded 1.25 and underrepresented 
(losses) when the profile ratio was less than 0.75. 
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Interpretation should consider that C G H analysis is uninformative in regions of the 
genome with high concentration of repeat sequences, and also may be unreliable near the 
chromosome telomeres (Du Manoir et al 1995). 
The utility of C G H is based on the concept that regions with an increased copy number in 
a tumor may contain dominantly acting oncogenes, whereas regions with a decreased 
copy number may harbor putative tumor suppressor genes (Kallioniemi et al 1994, 
Kallioniemi et al 1992). 
Therefore, C G H is a powerful genome-wide screening method as it allows the study of 
gains and losses of D N A in a hybridization experiment. It does not required prior 
knowledge of genetic aberrations, and does not require cells in metaphase. This technique 
is especially sensitive for detecting D N A amplification, and also for detecting deletions 



































































































































































































































































































































































































III.2 Loss of Heterozygosity (LOH) 
Loss of Heterozygosity (LOH) is frequently used as an indicator of loss of genetic 
material. This analysis is based on detection in the difference of the maternal and paternal 
alleles between normal constitutional D N A and tumor DNA. L O H is defined if one of the 
two alleles in normal constitutional D N A is absent in the tumor DNA. 
Dinucleotide {CA)n repeat analysis using polymorphic microsatellite markers is often the 
choice for L O H detection. (CA)n, where n varies from 10 to 60 copies, are plentiful 
throughout the human genome (Litt et al 1991, Weber et al 1989). Approximately 
50,000-100,000 separate (CA)« repeat sites are estimated to exist and are evenly 
distributed. Using sequence specific primers closed to the dinucleotide repeats, allelic 
fragments can be amplified by Polymerase Chain Reaction. As there is difference in the 
number of tandem (CA)« repeats, maternal and paternal alleles can be easily identified 
after separation on a denaturing polyacrylamide gel. 
L O H for a given marker in 25% or more of informative cases is usually considered as a 
significant loss of alleles (Ferrell et al 1999). Identification of high frequency of L O H in 
a particular chromosomal region in a tumor might suggest the presence of candidate 
tumor suppressor genes. 
37 
III.3 Methylation-Specific PCR (MSP) 
MSP is a relatively simple method to detect D N A methylation (Herman et al 1996). 
M S P involves bisulfite modification of D N A followed by PCR amplification with 
specific primers. During the bisulfite modification, all unmethylated cytosines are 
deaminated and converted to uracils, while methylated cytosines remain unaltered in the 
process (Figure 8). Therefore, two strands of D N A are no longer complementary after 
bisulfite treatment. PCR is then performed using primers designed to distinguish 
methylated D N A from unmethylated DNA. One reaction uses primers ("U" primer set) 
designed to anneal to the template if it is unmethylated while the other reaction will 
include primers ("M" primer set) designed to anneal if the template is methylated. If the 
sample D N A was originally unmethylated prior to modification, only the "U" primer set 
will produce an amplification product. Conversely, a product will be produced only with 
the "M" primer set if the D N A was originally methylated. Therefore, by doing MSP, the 
methylation status of the promotor regions can be detected. 
Compared to other methods, MSP is a simple, sensitive and specific method for 
determining the methylation status of any CpG rich regions (Herman et al 1996). 
Therefore, this technique was selected for detecting the methylation status of the 
promoter regions in this study. 
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Methylated CpG Unmethylated CpG 
—A — C'n—G—A—C — —A — c—G—A—C— 
Bisulfite Modification 
— A — C"—G—A—U— — A — U—G—A—U— 
Figure 8. Sequential changes after bisulfite modification. During the bisulfite 
modification, all unmethylated cytosines are deaminated and converted to 
uracils, while methylated cytosines remain unaltered in the process. Therefore, 
specific primers can be designed to distinguish methylated from unmethylated 
DNA 
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IV. OBJECTIVES OF STUDY 
Loss of chromosome 6q appears to be a frequent event in gastric carcinomas. In this 
study, we intend to investigate the chromosomal abnormalities involved in gastric 
carcinomas, particularly for chromosome 6q，by comparative genomic hybridization. 
Moreover, as most previous allelotyping studies included only one or two markers in this 
region, we use seventeen microsatellite markers in order to map the frequent minimal 
deletion regions on chromosome 6q involved in gastric carcinogenesis. 
Previous studies postulated that gastric intestinal metaplasia is a precancerous lesion of 
the gastric carcinoma as it is usually associated with gastric carcinoma (Semba et al 
1996). However, studies of intestinal metaplasia were limited on microsatellite 
instability, methylation and mutations of p53, APC and Ras genes. Therefore, L O H 
analysis of 6q on foci of intestinal metaplasia with gastric carcinoma of the same stomach 
may shed light on the relationship, if any, between intestinal metaplasia and gastric 
carcinoma. 
In the first part of m y study, ten cases of gastric carcinomas were analyzed by C G H to 
detect overall chromosomal imbalances. In the second part, we aimed to identify critical 
regions of allelic losses on the long arm of chromosome 6 in twenty-five gastric 
carcinomas by performing L O H analysis with seventeen microsatellite makers covering 
chromosome 6q. Intestinal metaplasia foci，where present, of the stomach in the same 
cancer patient were also examined. 
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V. MATERIALS AND METHODS 
V.l Sample Collections 
Tumor samples and corresponding normal tissues were obtained from 25 patients with 
gastric carcinomas. All the patients were treated surgically between year 1996 and 2000 
at the Prince of Wales Hospital, Hong Kong. None of the patients had received 
preoperative chemotherapy or radiotherapy. 
All gastric tumor samples and twenty-four normal tissue samples were obtained 
immediately after surgical excision. The selected tissues were snap frozened in liquid 
nitrogen and stored at -80°C. One case of normal D N A was obtained from blood as the 
corresponding normal tissue showing microsatellite instability in L O H study. Blood 
sample was collected in 10 ml EDTA tube and stored at -70°C immediately. Five cases of 
gastric intestinal metaplasia were obtained from formalin-fixed and paraffin embedded 
sections. These paraffine embedded blocks were stored at room temperature in the 
archival tissue bank. 
Intestinal metaplasia, normal and tumor status were confirmed by histopathological 
analysis. Tissue blocks contained most tissue contents were selected. Intestinal 
metaplasia from the cancer patients had been sampled from areas distant from the tumor 
during pathological assessment. Corresponding samples of benign gastric mucosa (that 
were confirmed microscopically to be free of tumor) were selected from each case as 
control tissue. 
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K L1 Patients Information for CGH Studies 
C G H analysis was performed on ten frozen gastric carcinomas tissues. 
Five patients were male and five were female. Their age ranged from 41 to 86. One tumor 
were located proximally (cardia), while one occurred in the body and eight in the 
antropyloric region. Gastric carcinomas were classified according to Lauren's 
classification, including six cases of intestinal type and four cases of diffuse type of 
gastric carcinoma. Two tumors were early gastric carcinoma, which were limited to the 
gastric mucosa and submucosa. Eight tumors were advanced gastric carcinoma invading 
through the muscularis propria into the serosa. The clinical features of patients, which 
were highlighted, were shown in table 6. 
K 1.2 Patients Information for LOH Studies 
Matched control and tissue samples were obtained from twenty-five patients with gastric 
adenocarcinoma (include the ten cases from C G H study). 
Eleven patients were male and fourteen were female. Their age ranged from 38 to 86, 
with a medium of 62. Seven tumors were located proximally, three occurred in the 
body/fundus and fifteen in the antrum and pylori. Ten cases were intestinal type and 
fifteen cases were diffuse type of gastric carcinoma. Four tumors were early gastric 
carcinoma and twenty-one tumors were advanced gastric carcinoma. The clinical features 
of the patients were presented in table 6. 
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For determination of Helicobacter pylori infection, presence of HP is identified by 
histopathologic examination of the gastrectomy and any previous biopsies, Giemsa stain 
applied in doubtful cases. For confirmation, ELISA test (ELISA, SIA™ Helicobacter 
pylori kit, Sigma Diagnostics, U.S.A.) with anti-HP IgG antibody is also performed on 









































































































































































































































































































































































































































































































































































































































































































































































































































































































V.2 Micro-Dissection of Frozen or Paraffin-Embedded Sections 
Micro-dissection was performed in order to maximize the percentage of tumor in each 
sample. In each case, twenty serial 10|Lim frozen or paraffin sections were cut. The first 
and last tissue sections were stained with hematoxylin and eosin to assure the tumor 
content and to guide the micro-dissection. All tumor sections were reviewed by a 
pathologist, and the presence of tumor was confirmed. For tumor, areas containing at 
least 70% of malignant cells were selected to minimize the contamination of 
inflammatory cells. Areas containing at least 70 % of intestinal metaplasia glands were 
also selected. Selected areas were micro-dissected manually using a needle under 
microscopic visualization. 
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Figure 9. Microdissection of gastric carcinoma. (A) Before microdissection, malignant 
cells are arranged in irregularly sharped nests surrounded by stromal cells. 
Microdissection was performed manually by a needle. (B) Tumor cell nests were 
dissected out leaving large holes behind. 
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V.2 Extraction of Genomic DNA for Tumor and Normal Tissues 
High molecular D N A was extracted from the blood samples or micro-dissected frozen 
and paraffin embedded tissues with standard proteinase K digestion and phenol 
chloroform protocol. The protocol of D N A extraction was described in details below: 
V.2,1 Extraction of Genomic DNA from Frozen Tissues or Paraffin Embedded 
Sections 
50|il of lOmg/ml proteinase K (Sigma, St. Louis, USA) along with 450^1 CTAB buffer 
were added to micro-dissected samples. The mixture was incubated at 55°C with rotation 
overnight for digestion of protein. Equal volume of phenol chloroform isoamylalcohol 
(25:24:1) was added for extraction of protein. After centrifugation at 13000 rpm for 10 
minutes, the upper aqueous layer containing D N A was collected and transferred to a new 
eppendorf. Equal volume of choloform : isoamylalcohol (24:1) was added for removal of 
phenol. After centrifugation at 13000 rpm for 10 minutes, the upper aqueous layer 
containing D N A was collected and then transferred to a new eppendorf. D N A was 
precipitated at -70°C for thirty minutes with addition of one-tenth volume of 3 M sodium 
acetate, pH 5.2, two and a half volume of chilled absolute alcohol and 3 jLil of lOmg/ml 
glycogen. The D N A pellet was washed with 70% ethanol, dried with a D N A Speed-Vac 
Concentrator (Savant Instruments Inc., Farmingdal, NY, USA). The dried D N A was 
resuspended in 25|il of autoclaved Milli Q water and was further incubated with Rnase 
for an hour at 37°C. After another phenol chloroform extraction, the dried D N A was 
reuspended in 30|al of autoclaved Milli Q water and stored at -20°C until use. 
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v.2.2 Extraction of Genomic DNA from Blood 
Normal D N A for use as a reference was prepared. Briefly, the frozen blood samples were 
thawed to room temperature and transferred to 15ml Falcon. Removal of haemoglobin 
was done by washing three times with IX PBS (phosphate buffered saline). The 
supernatant was discarded after centrifuging at 13000rpm for 10 minutes. The cell pellet 
was then subjected proteinase K digestion and phenol-chloroform extraction. Finally, 
D N A was resuspended in autoclaved Milli Q water and stored at -20°C until use. 
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v.3 Comparative Genomic Hybridization (CGH) of Gastric 
Carcinoma 
V, 3.1 Preparation of Normal Metaphase Slides 
Normal metaphase slides were prepared from peripheral blood lymphocytes of a healthy 
donor. The lymphocytes were cultivated in culture medium containing RPMI 1640 
medium, 20% fetal calf serum, L-Glutamine (Gibco BRL), 1.5% phythemaglutinin, 
penicillin and streptomycin (Gibco BRL) at 37。C, 5% carbon dioxide for 72 hours. 
Metaphase cells were harvested by adding 500|LI1 of colcemid. After 20 minutes of 
incubation at 37°C, cells were collected and treated with 0.05M and 0.06M Potassium 
Chloride, respectively. Removed supemantant and resuspended pellet in fixative 
(methanol/acetate acid 3:1). Repeated washing with fixative for at least 4 times, until a 
white cell pellet was obtained. Finally the metaphase cells were spread onto clean glass 
slides. Air dried the slides and stored at 4°C until use. 
V3,2 Metaphase Slide Denaturation 
The metaphase slides were immersed into 2xSSC (Sodium Saline Citrate) for 5 minutes 
at room temperature. Incubated with 150|al Rnase (O.lmg/ml) in a moist chamber at 37°C 
for 45min to an hour. Rinsed three times with 2xSSC, for five minutes each. Slides were 
digested with pepsin (10|ul in 40 ml 0.01 M HCl) at 37°C for 5 minutes and the reaction 
was terminated by rinsing in the following solutions: IxPBS (Sminutes, 2 times), 
MgCLs/PBS (5 minutes), MgCli/FM/PBS (10-15 minutes) and IxPBS (5 minutes). 
Slides were further dehydrated in a series of ethanol (70%, 90% and 100%). The air-dried 
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slides were denatured in 70% Formamide/2xSSC at 70°C for a minute. They were then 
dehydrated immediately in a series of iced ethanol (70%, 90% and 100%), for 2 minutes 
each. The air-dry slides were ready for hybridization. 
V.3.3 Nick Translation for DNA Labeling 
Tumor and normal reference D N A were labeled with biotin-16-dUTP and digoxigenin 
(dig)-dUTP (Boehringer-Mannheim, Mannheim, Germany) by nick translation, 
respectively. 
The nick translation of tumor D N A was carried out in a final volume of 50 jul containing 
2\xg of test DNA, Ix nick translation buffer, 0.5mM each of dATP, dCTP, dGTP and 
dTTP, O.IM p-mercaptoethanol, biotin-16-dUTP, 40mU DNase and Polymerase 1. 
For control DNA, 50 |li1 nick translation mixture contains 2\xg of control DNA, Ix nick 
translation buffer, 0.5mM each of dATP, dCTP, dGTP and dTTP, O.IM p-
mercaptoethanol, digoxigenin (dig)-dUTP, 40mU DNase and Polymerase I. The nick 
translation mixture was incubated at 15°C for an hour or longer. 
Labeling conditions were adjusted to yield probe sizes ranging from 400 to 2,000 base 
pairs. The reaction was stopped by adding 1 j^l of 0.5M EDTA and 0.5 jul of 10%SDS to 
the reaction mixture and followed by 65°C incubation for 10 minutes. 
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V, 3.4 Dot Blot Assay for Biotin and Digoxigenin-Labeled DNA 
Dot blot assay was performed to assess labeling efficiency of the nick translation 
products. 
The purified Biotin and digoxigenin labeled D N A was diluted to Ing. One drop of diluted 
D N A was dotted onto a Hybond N + nylon transfer membrane. The D N A was fixed onto 
the membrane by U V stratalinker 2400. After rehydration in AP 7.5 buffer, the 
membrane was incubated with 3% BSA. Alkaline phosphatase conjugated antibodies 
against Biotin (1:1000) or digoxigenin (1:10,000) was then incubated with the membrane 
for 15 minutes at room temperature. After washing twice with AP 7.5 and AP 9.5 buffers, 
signal was developed with BCIP/NBT (Boehringer Mannheim) (1:50) in the dark. The 
labeling efficiency of the tested D N A was compared with a control DNA. 
K3,5 Probe Preparation, Denaturation and Hybridization 
Biotin-labeled tumor D N A and digoxigenin-labeled normal reference D N A (800ng each) 
were precipitated with 60^1 Cot-1 D N A (BRL, Gaithersburg, MD)，3M sodium acetate 
and 100% ethanol. Excess of Cot-1 D N A is required to prevent the ubiquitous 
hybridization of interspersed repetitive sequences contained in the tumor and reference 
D N A probes. Repeat sequences, if not adequately blocked, tend to result in large ratio 
changes at the peri-centromeric and heterochromatin regions. 
51 
The probe pellet was dried and re-dissolved in 12)li1 of Hybrisol ® VII hybridization 
buffer. The probe mixture was denatured at 75°C for 5 minutes and put into an ice for 5 
minutes. For pre-annealing, the probe mixture was denatured at 15�C for 10 minutes and 
further incubated at 37°C for 45 minutes to 1.5 hours. The whole probe mixture was then 
applied onto the denatured metaphase slides. Hybridization was carried out for 3 days in 
a 37°C incubator. 
V.3.6 Post hybridization Washing and Detection 
Post hybridization washing was carried out in IxPBS at room temperature, twice in 
2xSSC at 67°C to 70°C and followed by IxPBS at room temperature for 5 minutes each. 
The slides were then incubated for an hour at 37°C with lOOjal of avidin-fluorescein 
isothiocyanate (Avidin-FITC) (1:150) yielding green fluorescence and with anti-
digoxigenin-rodamine (1:100) yield red fluorescence. Washing three times with Ix PBD 
and followed by dehydration in a series of ethanol (70%, 90% and 100%), the slides were 
air dried and finally counterstained with anti fade DAPI (4, 6-diamino-2-phenylindole) 
(Vectashield, Vector Laboratories, Birmingham, UK) solution. 
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V.3,7 Image Acquisition and Analysis of CGH Images 
Evaluation and screening of the C G H results were performed using a fluorescence 
microscope with a lOOx objective (Zesis，Jena, Germany), a filter set for 
DAPI/TRITC/FITC fluorochrome combination (Leica, Wetzlar, Germany) and a C C D 
camera interfaced onto a computer. 
Separate DAPI, TRITC and FITC digital images from 20 metaphases were recorded 
(Figure 10). Only good-quality metaphases with strong uniform hybridization were 
analyzed. Heavily bent or overlapping chromosomes were excluded. Averaged 
fluorescence ratios along each chromosome were then quantitatively analyzed by a digital 
imaging system ISIS 3 (Metasystems, Sandhausen, Germany). Threshold levels for the 
identification of chromosomal imbalances were set at 0.75 and 1.25. Chromosomal 
regions where the mean ration fell below 0.75 were considered as losses of DNA, 
whereas regions with the mean ratio exceeded 1.25 were considered as gains of DNA. 
These values were established on the basis of C G H experiments using normal D N A and 
D N A from gastric cell lines with known chromosomal aberrations. Due to the 
suppression of Cot-1 DNA, heterochromatic regions in the centromeric and 
paracentromeric parts of the chromosome 1,9,16 and the short arms of the acrocentric 
chromosomes were excluded in the analysis. Because the tumor specimens and normal 
reference D N A were not sex-matched, the X and Y chromosomes were omitted from 
analysis. 
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• H H 
Figure 10. Separate (A) DAPI, (B) TRITC and (C) FITC digital images from a 
metaphase preparation. 
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V.4 Loss of Heterozygosity (LOH) Analysis on Chromosome 6q 
Loss of Heterozygosity (LOH) analysis was performed in all case in which paired 
normal/tumor samples were available. Among these cases, frozen tissues were available 
in all case. In one cases, peripheral blood collected immediately before gastrectomy was 
also used as the normal control for allele assignment. Matched blood samples were not 
available for the remaining cases. In five cases (cases 2, 3，6, 11 and 23), foci of gastric 
intestinal metaplasia were selectively removed from paraffin sections. 
V, 4.1 Microsatellite Markers 
Seventeen microsatellite markers covering chromosome 6q were used for normal and 
tumor (paired) analysis. Primers were obtained from MapPairs (Research Genetics Inc., 
Huntsville, AL, U.S.A.). The microsatellite markers analyzed in the present study 
includes D6S286, D6S300, D6S468, D6S301, D6S447, D6S268, D6S278, D6S261, 
D6S270, D6S441, D6S415, IGF2R, D6S305, D6S264, D6S297, D6S446 and D6S281. 
The order of the markers used for L O H analysis and their distance in cM from 
centromere was based on the information from both Research Genetics and 
Whitehead/MIT databases. The map positions, genetic distances between markers, PGR 
conditions and PGR primers sequences were based on published human genetic maps of 
chromosome 6 and are shown in table 7. More microsatellite markers were chosen in this 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































V,4,2 Polymerase Chain Reaction (PGR) 
The extracted D N A was amplified by the polymerase chain reaction (PCR). Non-
radioactive PGR was employed in this study. 
PCR reaction was performed in a final volume of 10|il containing 30ng of genomic DNA, 
0.2|^ mol/L of each primer, 2mmol/L MgCb, 250jimol/L of deoxynucleoside triphosphate 
(dNTPs), 1 X PCR Gold buffer and 0.5unit ofAmpliTaq Gold (Perkin-Elmer, Foster-City, 
CA). A drop of sterile mineral oil was added to each tube in order to prevent the 
evaporation of sample during PCR. 
The PCR reaction was performed in a D N A thermal cycler (MJ Research, Watertown, 
MA, USA) with the following conditions: After an initial heating at 94°C for 10 minutes, 
30 PCR cycles of denaturation, primer annealing, and extending were performed at 94°C 
for 1 minute, 53-59°C for 1 minute, and 72°C for 1 minute. All PCR reactions concluded 
with a final extension step at 72°C for 10 minutes. PCR products were then mixed with 
61^ 1 of loading buffer, denatured at 95°C for 10 min, chilled on ice and subjected to 
electrophoresis. 
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v.4.3 Denaturing Polyacrylamide Gel Electrophoresis 
6% polyacrylamide gel containing 7 M urea was prepared. Prior the sample loading, the 
gel was pre-warmed for half an hour at 1500V. Sjul of PGR products was loaded onto the 
denaturing gel. Electrophoresis was carried out for two to three hours at 1600V, 
depending on the size of PGR products. After the electrophoresis, the gel was transfer 
onto a 3 M M Whatman paper (Springfield Mill, England). 
V.4,4 SYBR Gold Nucleic Acid Gel Staining and Image Viewing 
SYBR Gold stain is the most sensitive nuclei acid gel stain available for detecting 
ssDNA, dsDNA and R N A (Tuma et al 1999). It is more sensitive than ethidium bromide, 
which is currently the most common gel staining for non-radioactive electrophoresis. 
SYBR Gold stain's superior sensitivity is due to the high fluorescence quantum yield of 
the dye-nuclei acid complex, the dye's large fluorescence enhancement upon binding to 
nuclei acids (-1000 fold) and its capacity to more fully penetrate gels than do other gel 
stains. 
5|al of SYBR Gold stain was diluted (1:10,000) with IX TE (lOmM Tris, I m M EDTA). 
The gel was incubated in this dye-containing solution for fifteen minutes. 
After staining with SYBR Gold stain, the gel was scanned using the Typhoon 8600 
variable mode imager (Molecular Dynamics, California) Scan utilized the green (532nm) 
laser at 800V. The image was viewed using Image Quant 5.1 (Molecular Dynamics). 
58 
V. 4,5 Assessment of Loss of Heterozygosity (LOH) 
The analysis of allelic losses is based on comparison of signal intensities of the maternal 
and paternal alleles between constitutional D N A and tumor DNA. The maternal and 
paternal alleles were visualized as two distinct bands. The assessment of the allelic 
intensities was based on the signal intensities of these two major distinct bands. Results 
for all cases were analyzed visually. 
Sharp decreased intensity or absence of one allele was interpreted as Loss of 
Heterozygosity (LOH). Retention of heterozygosity (R) was scored when the signal 
intensities of the bands of the constitutional and tumor D N A appeared to be similar. Not 
informative (NI) was scored when the normal sample was homozygous at the locus. 
Microsatellite instability (MSI) was defined as the presence of allelic shift, allelic 
expansions and noval allele. The experiment was repeated at least twice to assure that 
results were reproducible in each case that showed LOH. Figure 11 illustrates retention of 













































































































































































































































For the suspicious case, calculation of L O H can based on the following formula using 
Image Quant (version 5.0) software: 
L = (At2xAnl)/ (AtlxAn2) 
Where A was the area, t was the tumor sample, n was the normal sample, 1 and 2 were 
the two main alleles, respectively. Values of L <0.60 or > 1.70 indicated that one of the 
alleles has decreased more than 40%, resulting in LOH. 
V. 4,6 Statistical Analysis 
Chi-Square test was applied for the statistical analysis in this study. The data was 
processed using Statistical Package for Social Science (SPSS 10.1). />-value less than 
0.05 was considered statistically significant. 
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V.5 Methylation Specific Polymerase Chain Reaction (MSP) 
As microsatellite instability is usually associated with hypermethylation of hMLHl gene 
promotor，MSP was performed in case 14. Methylation Specific Polynerase Chain 
Reaction (MSP) included two steps, namely, bisulfite modification of D N A and MSP. 
V.5.1 Bisulfite Modification of DNA 
Genomic D N A was subjected to bisulfite modification using CpGenomic D N A 
Modification Kit (Intergen Company, New York, NY). 
V. 5.1.1 Reagent Preparation 
3 M sodium hydroxide stock was freshly prepared prior to each use by Ig of sodium 
hydroxide pellet in 8.3ml of autoclaved double-distilled water. For each sample to be 
modified, 227mg of reagent I (freshly prepared), 571 of autoclaved double distilled 
water and 20 of 3 M sodium hydroxide were mixed together. D N A modification 
reagent II was prepared by adding 750 |li1 of diluted P-mercaptoethanol (Ijil of P-
mercaptoethanol in 20 ml of autoclaved double distilled water) to L35g of Reagent II 
powder for each sample. 
V.5.1.2 DNA Modification 
7 ii\ of 3 M sodium hydroxide were added to 100 of D N A sample (lOng/jul) in a 1.5 ml 
screwcap eppendorf. After mixing, the mixture was denatured at 37° C for ten minutes. 
The denatured D N A was then incubated with 550^1 of D N A Modification reagent I 
(Intergen Company) at 50° C for 16 to 20 hours. 
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V.5.1.3 Completion of Chemical Modification and DNA Clean-Up 
5 fil of well-suspended D N A Modification Reagent III and 750 |il of D N A Modification 
Reagent II were added with brief mixing. The mixture was incubated at room temperature 
for ten minutes, followed by centrifugation at 10,000 rpm for one minute to pellet the 
D N A Modification reagent III. The supernatant was discarded. The pellet was then 
treated with step-wise addition of 1 ml 70% ethanol, re-suspension and centrifugation at 
10,000 rpm for 1 minute. The supernatant was removed. The washing steps were 
performed for a total 3 times. Modification was completed by incubating with 50 j^l of 20 
m M sodium hydroxide / 90% ethanol for five minutes followed by pelleting the sample 
by centrifugation at 10,000 rpm for a minute. 
The modified D N A was precipitated with 1 ml 90% ethanol, vortexed and centrifuged at 
13,2000 rpm for five minutes. The supernatant was removed. These steps were performed 
twice. The modified D N A was eluted with 50 |LI1 autoclaved double distilled water at 
50°C for fifteen minutes. The supernatant was transferred to a new sterile eppendorf after 
a 3 minutes full-speed centrifugation. The modified D N A was then stored at -20°C. 
V.5.2 Mehtylation Specific PCR 
Methylation-specific PCR was carried out essentially as previously described (Herman et 
al 1996). Amplification of bisulfite-modified D N A was carried out using the primer pairs 
specific for the methylated and unmethylated hMLHl promoter sequences (Fleisher et al 
1999). 
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V.5.2.1 HMLHl Primer 
Primer sequences of hMLHl for the ummethylated reaction were 5,-TTT T G A TGT 
A G A TGT TTT A T T A G G GTT GT-3' (sense) and 5，-ACC ACC T C A T C A T A A 
C T A C C C ACA-3’ (antisense), whereas for the methylated reaction they were 5'ACG 
T A G A C G TTT TAT T A G G G T CGC-3’ (sense) and 5,-CCT C A T C G T A A C T A G 
C C G CG-3' (antisense). 
V.5.2.2 PCR Amplification 
PGR mix contained 2.5 |il of lOxPCR buffer, 2.5 |LI1 of 2 5 m M MgC12, 2.5 of2.5mM 
deoxyribonucleotide triphosphates (dNTPs), 1 |LI1 of 10 |iM each of sense and antisense 
primers, 0.5 unit Ampli Taq Gold D N A polymerase (Perkin Elmer), 2 jul of the modified 
D N A and 14.4 |il autoclaved double distilled water. The final volume added up to 25 jul. 
The PCR was performed in a D N A Thermal Cycler (PE480, Perkin-Elmer) under the 
following conditions: an initial denaturation at 95°C for 12 minutes, followed by 35 
cycles of denaturation at 95°C for 45 seconds, annealing at 55°C for 55 seconds and 
extension at 72°C for a minute, then with a final extension at 72°C for 10 minutes. 
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V.5.2.3 Polyacylamide Gel Electrophoresis 
Both methylated and unmethylated products were analyzed in pair by gel electrophoresis. 
2 |il of 6x loading dye (Blue/orange 6x loading dye, Promega, Madison, WI, USA) was 
added to 10 |il of each reaction product. The mixture was then loaded into a vertical 10% 
non-denaturing polyacrylamide gel. A D N A size marker, (|)174-HaeIII digest, was also 
included for the assessment of the product sizes. 
The electrophoresis was carried out in Ix TBE buffer at 200 volts for 30 minutes. The gel 
was stained with ethidium bromide for 15 minutes and was then visualized and 
photographed under U V illumination. 
V.5.2.4 Control 
Water (autoclaved Milli Q water) was used as a negative control for each set of assay. 
Universal methylated D N A (Intergen Company, New York, NY) was used as a positive 
control for the methylated reaction. 
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VI. RESULTS 
VLl Results of CGH 
VLl.l Chromosomal Copy Number Aberrations in Gastric Carcinoma 
C G H was performed to detect genetic imbalances in gastric carcinoma. Changes in D N A 
copy numbers were detected in all intestinal and diffuse type gastric carcinomas. An 
overview of genetic changes in the ten gastric carcinomas is shown in table 8 and figure 
12. Nine cases (90%) showed evidence of an increased D N A copy number, and seven 
cases (70%) showed a decreased D N A copy number in 1 or more regions of the genome. 
Figure 13 shows an example of the results from a C G H analysis, hybridization with D N A 
from a gastric carcinoma (green) and normal reference D N A (red) to normal metaphase 
chromosomes. Figure 14 illustrates green to red ratio profiles for all chromosomes. 
Gains of copy number were more frequent than losses. The most frequent common 
regions of gains of D N A copy number occurred at lp36-pter (70%), 17ql2-21 (80%), 
19q (60%), 20pq (50%) and 22pq (60%). Losses were most often detected at 4q (30%), 
6q (40%), 9p (30%) and llq (20%). Figure 15 illustrates green to red ratio fluorescence 
image and the corresponding average ratio profiles for chromosome 6. 
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VLL2 Comparison of CGH Results with Intestinal and Diffuse Type of Gastric 
Carcinoma 
Increases in D N A copy number were observed at lp36-pter, 17, 19 and 22 for both 
intestinal and diffuse types of gastric carcinoma. Increases at llq (33%) and 20 (66%) 
and decreases at 6q (50%) and 9p (33%) were predominantly of intestinal type. On the 
other hand, increases at 1 Ip (50%) were rather specific to the diffuse type of gastric 
carcinoma. Thus suggests that they might have different genetic pathways involved in 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VI.2 LOH Analysis of Chromosome 6q 
To identify the smallest deletion region in chromosome 6q, L O H was performed in 
twenty-five gastric carcinomas using a panel of seventeen microsatellite markers 
spanning the long arm of chromosome 6. The markers and their respective frequencies of 
L O H among these tumors are listed in figure 16，in descending order from centromere to 
telomere. 
All patients were informative in multiple loci on chromosome 6. The markers used in this 
study were informative in 44% (D6S281) to 80% (D6S261) of the cases. Eighteen out of 
twenty-five cases (72%) showed allelic losses for at least one marker. The percentage of 
cases displaying L O H at 6q ranged from 0% at loci D6S468, D6S268, D6S261, D6S415 
and IGF2R to 40.1% at locus D6S446. The frequencies of L O H greater than 25% were 
observed at D6S300 (38.5%), D6S264 (25%) and D6S446 (40.1%), located on 6ql6.3-
q21, 6q25.2-27, and 6q27, respectively. 
To map the regions involved in the deletions at chromosome 6q, cases were grouped into 
3 different categories on the basis of their patterns of LOH (Figure 17). Tumors showing 
no detectable LOH at chromosome 6q (Group 1) were not useful for mapping purposes 
(not shown). Group 2 is composed of tumors exhibiting random pattern of loss and 
retention of heterozygosity. The LOH patterns of tumors in Group 3 showed common 
deletion regions at D6S300 and D6S446 (Figure 17). Two common deletion regions 
termed A and B were observed, as indicated by vertical bars. 
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The first common deletion region (region A) was centered at marker D6S300 (6ql6.3-
q21) and involved adjacent markers D6S286 and D6S468. Figure 18 shows pictures of 
representative cases demonstrating first common deletion regions at D6S300. Cases 17 
and 23 showed allelic loss at locus D6S300. Case 17 showed retention of heterozygosity 
at D6S286, which defined the proximal margin of the loss region. Moreover, all three 
cases showed retention of loss at locus D6S468, thus suggested that D6S468 was the 
distal margin of the deletion region. As a result, this deletion region was located at 
chromosome 6ql4-q21 and lie between D6S286 and D6S468. The physical distance 
between D6S286 and D6S468 is approximately 18cM. The frequency of L O H in this 
region was 26.1%. 
The second deletion region (region B) was located at the telomeric part (6q27) of the long 
arm of chromosome 6. Cases 2, 5 and 11 showed allelic loss D6S446, but retention of 
heterozygosity at both D6S297 and D6S281 (Figure 19). Therefore, this loss region was 
located at D6S446 (6q27) and lie between D6S297 and D6S281 (which is approximately 
19.7 cM apart). The frequency of L O H in this region was 41.7%. 
Cases 2，3, 6，11 and 23 showed retention of allele in intestinal metaplasia but allelic loss 
in tumor at locus D6S446 (Figure 120). 
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Microsatellite instability was an uncommon event (0%-8%), but detected in one tumor 
(Case 14) at multiple loci (D6S300, D6S468, D6S301, D6S447, D6S278, D6S261, 
D6S270，D6S415, D6S305, D6S297 and D6S446) (Figure 21). This patient had no 
clinical history suggestive of familial gastric cancer. 
W e also investigated the correlations between L O H at these two deletion regions and 
clinicopathological features: age, sex, histological diagnosis, tumor sites, H. pylori 
positivity, metastasis and stage. However, no statistically significant associations were 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VII. 1 Discussions on CGH Study 
In an attempt to localize genetic imbalances materials in gastric carcinomas, C G H 
analysis was performed. This technique allows the comprehensive analysis of tumor 
genome for D N A copy gains and losses. As microdissection was performed, high tumor 
cell content is assured. Our results in the present study reveal high frequencies of non-
random chromosomal aberrations in gastric carcinoma including chromosomes Ip, 17q, 
19q, 20, 22, 4p, 4q and 6q. 
Tables 9 and 10 show the comparison between copy number gains and losses in the 
present study with previous reports. Many of the copy number gains identified in this 
study such as Ip, 16p, 17q, 19q, 20q and 22q occurred at similar frequencies as in 
previous studies (Kim et al 2001, W u et al 2001，Guan et al 2000, Koo et al 2000, 
Nakanishi et al 2000, Okasa et al 2000, Van Grieken et al 2000, Sakakura et al 1999， 
Nessling et al 1998，Kokkola et al 1997, Koizuami et al 1997). However, some areas of 
gain such as 12q occurred at a higher frequency in this study whilst other areas such as 
7p, 8q and 13q showed relatively less frequent gains. Similarly for the copy number 
losses, many occurred at a frequency comparable with previous studies but others 
occurred at a relatively lower frequency. Loss of copy numbers at 4q, 6q and 9p occurred 
at a similar frequency as previously, while losses at 5q, llq, 15q and 19p. However, copy 
number losses at 17p, which harbor p53, were not detected. Small sample size in this 
present study may account for the difference. However, mutations are probably more 
important in loss of a functional p53 gene than deletion. 
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Moreover, there were clear differences in the frequency of copy number change within 
other studies. Okada et al observed higher frequency of 4q and 21p loss, but a lower 
frequency of 8p gain and 17p loss in comparison with other groups (Okada et al 2000). 
Also, Kim et al observed a relatively higher frequency loss at 17p but a low frequency at 
4q (Kim et al 2000). Therefore, our results have shown some areas of copy number 
changes that have not been previously reported. This might perhaps reflect the 
complexity of gastric carcinoma genetics. Most studies show similar patterns of copy 
number changes, however, there is still some differences in the results. It might suggest 
that gastric cancer do share some genetic aberrations, but different population groups 
might have distinct genetic changes. Notably, there is very little C G H data from China 
for closer comparison. 
In our C G H analysis of ten gastric carcinomas, gains of D N A copy number were 
observed more frequent than losses. The frequent gains of D N A copy number were 
observed at Ip，17q, 19q, 20 and 22, suggesting that these regions may harbor oncogenes. 
The short arm of chromosome 1，which was over-represented in 7 (70%) of 10 cases, 
harbors the candidate gene SLC2A1 at lp.35-p3L3. Previous studies on gastric 
carcinoma have also reported over-expression of this region (Sakakura et al 1999). 
Some cell regulation and growth factor genes have been mapped to the region of 17ql2-
21. The potential candidate genes are c-erbB2 and gastrin. Previous studies have shown 
over-expression of the c-erbB2 gene in gastric carcinoma (Ishikawa et al 1997，Thara et 
al 1995, Tsugawa et al 1993). Gastrin has been reported to stimulate the growth of gastric 
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carcinoma cell in vivo (Watson et al 1989), while elevated serum gastrin levels have been 
detected in gastric cancer patients, especially with the intestinal type (Rakic et al 1991). 
In our study, amplification of this region was observed in both types of gastric carcinoma, 
which is consistent with previous C G H analysis in gastric carcinoma (Sakakura et al 
1999). 
The high frequency of20pq amplification in our study was similar to that of other studies 
(Koo et al 2000, Sakakura et al 1999，Kokkola et al 1997). Amplification at chromosome 
20 has also been reported in other tumors, including breast, colon and ovarian cancers 
(Sonoda et al 1997, Schlegel et al 1995, Kallioniemi et al 1994). Thus far, no candidate 
genes have been confirmed. Nevertheless, frequent amplification of this region suggests 
the existence of some important genes related to the development of gastric carcinoma. 
The common deletion regions were observed at 4q, 6q，9p and llq. These regions are 
assumed to harbor tumor suppressor genes involved in the development and progression 
of gastric carcinoma. Chromosome 4q and 9p showing frequent losses in our C G H 
analysis agree well with published C G H findings (Koo et al 2000，Nakanishi et al 2000, 
Nicole et al 2000，Sakakura et al 1999, Kokkola et al 1997). Loss of 4q has been 
commonly observed in other tumors, including hepatocellular carcinoma, breast, ovarian, 
oesophagus and bladder cancers (Guan et al 2000). However, no critical target genes on 
4q have been identified yet. The pl6 gene is located at 9p2L It is a cyclin-dependent 
kinase inhibitor that acts as a tumor suppressor gene has been suggested to be involved in 
gastric carcinogenesis (Van Grieken et al 2000). Furthermore, increase frequency of pi 6 
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hypermethylation from gastric adenoma to gastric carcinoma has been previously 
reported and it was suggested that pl6 hypermethylation plays a role in the malignant 
transformation of gastric carcinoma (Kang et al 2001). 
The deletion of 6q (40%) was the most frequently observed finding in our study. This 
finding is in keeping with previous cytogenetic observation of frequent deletion of 6q in 
gastric carcinomas (Seruca et al 1993). This further supports that deletion of chromosome 
6q may be important in the development of gastric carcinoma, similar to what has been 
postulated for other tumors (Utada et al 2001). Compared with previous studies, the 
present study observed higher frequencies of deletion of 6q, as observed in gastric cell 
lines (Okada et al 2000). It may suggest that different population groups may have 
different genetic changes. It is difficult to address this because many factors may be taken 
account including tumor subtype, tumor stages, patient age, geographical location, H. 
pylori infection and other aetiological factors. Moreover, miscrodissection of gastric 
tissues allows higher yield and more representative population oftumor cells. This could 
also account for higher frequencies of aberration observed. In the present study loss of 6q 
was observed in all stages (I to IV) of gastric tumors, suggesting that it might be involved 
in the development of gastric carcinoma. 
Genetic aberrations were observed in all ten tumors. Changes of copy number were 
observed for examples gains of chromosomes Ip, 17，19, 20 and 22 regardless of the 




















































































































































































































































































































































































































































































































































































































































































































































































































VII.2 Discussions on LOH Study 
Since high percentage of 6q deletion was observed in our C G H study, we aimed to 
identify critical regions of allelic losses on the long arm of chromosome 6. W e 
investigated the L O H pattern along the long arm of chromosome 6 in twenty-five cases of 
gastric carcinoma with seventeen microsatellite markers. Using a precise micro-
dissection technique, L O H was detected in 72% of the twenty-five gastric carcinoma 
samples. The frequencies of L O H show greater than 25% of the informative cases were 
observed at D6S300 (38.5%), D6S264 (25%) and D6S446 (40.1%), located on 6ql6.3-
q21, 6q25.2-27, and 6q27, respectively. 
VIL 2,1 Two Distinct Deletion Regions 
In the current study, 6q losses in gastric carcinoma cluster in two distinct common 
deletion regions. These two distinct deletion regions were located at 6ql4-21 and 6q27， 
respectively. The first deletion region (Region A) was defined by loci D6S286 and 
D6S468 (18 cM apart), while the second deletion region (Region B) lied between the loci 
D6S297 and D6S281 (19.7 cM apart). The findings in this study are in general agreement 
with the study performed by Quiemado et al, who identified two distinct regions of 
deletion at 6q, one between 6ql6.3-q23.1, another distal to 6q23-q24 in gastric carcinoma 
(Quiemado et al 1995). Therefore, this data strongly suggest the presence of tumor 
suppressor genes, which may be specific and crucial for the development of gastric 
carcinoma, located at 6ql4-21 and 6q27. 
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Different geographical location with high incidence rate of gastric carcinoma detected the 
same deletion regions at 6q (Portugal and Hong Kong), suggesting that we shared a part 
of genetic aberrations and also the importance of loss of this region was pointed out in 
gastric carcinoma. Moreover, the present study observed higher frequencies of loss in 
these two regions than Queimado's group (26.1% and 41.7% vs 17.6% and 23.5%) 
(Queimado et al 1995). In their paper, they did not mention the stages of the gastric 
carcinomas studied but in the present study more advanced cases were investigated. 
Nevertheless, loss of 6q in gastric carcinoma is at least important in Hong Kong 
population. 
Figure 22 compared the deletion pattern of chromosome 6q in gastric cancers with other 
tumors，including acute lymphoblastic leukemia, prostate, pancreas, melanoma and so on. 
Different tumors shared the same or part of deletion regions reported in this study. 
VIL2.1.1 Region A 
6ql4-21 overlaps with a common deletion region described in prostate cancer (Cooney et 
al 1996)，mesothelioma (Bell et al 1997), malignant melanoma (Miele et al 2000) and 
haemopoietic malignancies. Recently, Rodriguez et al identified 4 deletion regions in 
breast cancer, with one of them located at D6S300, which is the most frequently lost 
region in the present study (Rodriguez et al 2000). This strongly suggests that the tumor 
suppressor gene located at 6q21 is not only involved in gastric carcinoma, but also in 
other tumors. In gastric carcinoma, previous L O H study defined a common deletion 
region at 6ql6.3-23.1 using markers D6S268, D6S32 and ARGl (Quiemado et al 1995). 
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Later, Carvelho and his fellows using 19 highly polymorphic markers to further delimited 
this deletion region (Carvelho et al 1999). A deletion region (at 6q21) of approximately 
2cM flanked by markers D6S278 and D6S404 was then identified. This deletion region 
overlaps the deletion region we found in the present study. 
The presence of the tumor suppressor genes located in this region is further suggested by 
the fact that introduction of a copy of normal chromosome 6 into melanoma cell line 
leads to reversion of the tumorigenic phenotype in vivo and suppresses the tumorigenicity 
of the cells in nude mice (Trent et al 1990). Similar findings were also reported by 
Gualandi et al (Gualandi et al 1994). They discovered that introduction of normal 
chromosome 6 into human papovavims transformed mouse cell reverts the immortal 
phenotypes, with the exception of several clones showing deletions involving the 6q21 
cytogenetic band. More recently, Miele et al found that metastasis is suppressed when an 
intact chromosome 6 was transferred into C8161 human melanoma cells (Miele et al 
2000). However, when chromosome 6 containing a deletion of the region 6ql6.3-q23 was 
introduced into metastatic human melanoma cells by microcell-mediated transfer, 
metastasis was not suppressed. These all support the existence of tumor suppressor genes 
in the region 6q 14-21. 
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VIL2.1.2 Region B 
9 out of 22 cases (40.1%) of gastric carcinoma showed evidence of L O H at the locus 
D6S446 at 6q27. This deletion region overlaps the deletion region (6q25-6q27) reported 
previously in gastric carcinoma (Quiemado et al 1995). Our results have narrowed down 
this deletion region to 6q27. These data indicate that inactivation of the genes in 6q27 is 
involved in gastric carcinogenesis. This deletion region is also consistent with the 
findings from previous conventional cytogenetic studies (loss of the chromosomal 
segment distal to band 6q21-22 (Ochi et al 1986，Seruca et al 1993，Panani et al 1993). 
Allelic loss involving 6q27, a region that overlaps with the distal common deletion 
regions we have described here, has been reported in other tumors. For example, L O H at 
6q26-27 was detected in breast cancer (Noviello et al 1996), hepatocellular carcinoma 
(Koyama et al 2000), parathyroid adenoma (Thara et al 1996) and B cell Non-Hodgkin 
lymphoma (Gaidano et al 1992). Cooke et al has further restricted the minimal deletion 
region to 6q27 in ovarian cancer (Cooke et al 1996). Moreover, Saito et al defined a 
commonly deletion 0.3Mb region on band 6q27 in ovarian cancers (Saito et al 1996). It 
might proposed that the same tumor suppressor gene(s) at 6q27 may be involved in more 
than one tissue type, suggesting that 6q27 alterations reflect a common general pathway 
of tumorigenicity. 
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As in previous studies, L O H of 6q was detected in both diffuse and intestinal types of 
gastric carcinomas. This supports that loss of chromosome 6q is an important non-
random event in the development of gastric carcinoma, independent of the histological 
differentiation. For cases with retention of chromosome 6q，alternative pathways of 
gastric carcinogenesis may exist. 
VIL2.2 Possible Candidate Suppressor Genes in Two Deletion Regions 
(Table 11) 
VII.2.2.1 At 6q21: 
Detection of common deletions in multiple types of malignancy might reflect inactivation 
of common tumor suppressor genes. Cyclin C (CCNC) is located at chromosome 6q21. 
Its role in regulation of cell cycle and is considered as a candidate tumor suppressor gene, 
which is deleted in a subset of acute lymphoblastic leukaemias (Li et al 1996). AIMl 
(absent in melanoma) gene, a novel non-lens member of the Py-crystallin superfamily, is 
located at 6q21. Py-crystallin superfamily membrane was suggested to play a role in 
management of cell morphology, differentiation and suppression of malignancy (Ray et 
al 1997). This gene is not expressed in tumorgenic but is highly expressed in suppressed 
melanoma cells. Also, introduction of chromosome 6q containing this gene suppressed 
malanoma tumor formation (Ray et al 1997). Therefore, it is a possible candidate for 
putative suppressor in malignant melanoma. A SEN6A gene, restores senescence to 
mortal ovarian tumor cells after chromosome transfer, is located at 6q21 (Sandhu et al 
1994). However, this gene has not been cloned to date. As the genes mentioned above are 
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located at 6q 14-21, the first common deletion found in this study, we cannot exclude their 
role in the tumorigenicity of gastric carcinoma. 
VIL2.2.2 At 6q27: 
Some candidate tumor suppressor genes have been recently mapped to 6q27, including 
SEN6’ AF-6, RNASE6PL, THBS2, PDCD2 and i?/z/r2/S'-glycoprotein ribronuclease 
genes. Banga and his fellows proposed a SEN6 gene that mediates senescence and 
suppress the immortal phenotype of simian virus 40-transformed human fibroblasts 
(Banga et al 1997). This gene is mapped to 6q26-27 and located between markers 
D6S133 and D6S281. The function of SEN6 is unknown. As this gene is located in the 
deletion region defined in this study, involvement of SEN6 in gastric carcinoma cannot be 
excluded. AF-6 gene (ALL-fused gene from chromosome 6), is localized at 6q27, is 
disrupted in /(6;ll)(q27;q23) in acute myeloid leukaemia (Prasad et al 1993). It's gene 
product play a regulatory role in cell-to-cell adhesion (Suzuki et al 2000). However, 
mutations of AF-6 gene should be investigated in order to confirm its role in the 
development of gastric carcinoma. 
RNASE6PL, a Class II tumor suppressor gene, has recently been mapped to 6q27. No 
gene mutation but significant reduced in expression was observed in ovarian tumor and 
cell lines (Acquati et al 2001). Moreover, transfection of this gene into ovarian cell lines 
suppressed tumorgenicity in mude mice. LaBell et al (1992) mapped the 
Thromobospondin II {THBS2) gene to 6q 27 by analysis of somatic cell hybrids and by in 
situ hybridization. Later, injection of 77/万幻-transfected was cloned into the dermis of 
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nude mice resulting in pronounced inhibition of tumor growth {Streit et al 1999). Also, 
extensive area of necrosis, significant reduced in density and the size of tumor vessels 
were observed. Therefore, THBS2 is a potent endogenous inhibitor of growth and 
angiogenesis. Other genes such as programmed cell death 2 gene (PDCD2) is involved in 
the inhibition of apoptosis. Mammalian Rh/T2/S-Glycoprotein ribonuclease family gene 
has also been cloned in a region of chromosome 6q27 (Trubia et al 1997). However, up 
to now, its function is unknown. 
Again as those genes are located in the deletion region observed in this study and 
expressed in normal stomach mucosa, it is highly suggested that one or more of these 
genes are involved in the development of gastric carcinoma. Further functional and 
expression studies of these genes on gastric cancers should be performed, in order to 
confirm their role in gastric carcinogenesis. 
VIL2.3 Infrequent Loss ofIGF2R Gene 
Our study did not detect any L O H at the locus IGF2R. Thus, it suggests that IGF2R gene 
though important in cellular growth and regulation, may not be a critical determinant in 
gastric carcinogensis. In contrast, deletions on IGF2R locus (6q26) were reported in 
39.7% of breast cancers (Utada et al 2000) and 61% of haptocellular carcinomas 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VII.3 Relationship Between Intestinal Metaplasia and Gastric 
Carcinoma 
This is a first study to detect loss of long arm of chromosome 6 in intestinal metaplasia. 
As gastric intestinal metaplasia is usually associated with gastric carcinoma, it was 
suggested that it is a precancerous lesion of gastric carcinoma (Stemmermann et al 1994). 
Genetic studies on mutations of p53, APC, expression of metallothionein, accumulation 
of microsatellite instability and hypermethylation of hMLHl further supported that 
intestinal metaplasia is a precancerous lesion (Kang et al 2001, Ebert et al 2000, 
Kobayashi et al 2000，Leung et al 2000，Semba et al 1996，Nishimura et al 1995, Tahara 
et al 1994). Therefore, by performing L O H studies on gastric carcinomas and intestinal 
metaplasia, we would like to investigate whether there is any relationship between them. 
Intestinal metaplasia did not show any allelic loss at locus D6S446, which is found in the 
autlogous cancerous lesion. This might suggest that loss of 6q at locus D6S446 occurs 
after the stage of intestinal metaplasia. As loss of this locus is found in tumors of all 
stages including early cancer, it is a relatively early event in the multi-step progression of 
gastric carcinoma. Thus, loss of 6q (particularly at locus D6S446) might be one of the 
critical events involved in the progression from intestinal metaplasia to cancer. 
As there is limitation in the sample size (only five cases of intestinal metaplasia were 
studied), the role of 6q in intestinal metaplasia needs further elucidation. Ideally, paired 
C G H studies on the foci of intestinal metaplasia should be performed together. However, 
this is practically difficult, as C G H requires large amount of good quality D N A from 
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fresh tissue. Intestinal metaplasia occurs in scattered foci and not always identifiable 
grossly. Microdissection of frozen tissue of intestinal metaplasia usually does not yield 
sufficient D N A for C G H experiments. DOP-PCR-CGH may be needed. 
VII.4 Microsatellite Instability 
Microsatellite instability has been linked to defect in D N A mismatch repair system that 
results in defective proteins that failed to correct replication errors, including those 
resulting from slippage during D N A replication. Previously study has shown 
microsatellite instability in approximately 10% of sporadic gastric carcinoma (Hailing et 
a/ 1999). Recent studies have suggested that silencing the human mut-L homologue 1 
QiMLHl) by promoter methylation may account for most defect mismatch repair 
(Bevilacqua et al 2000, Fleisher et al 1999, Leung et al 1999). Defect in the mismatch 
repair system thus might play a role in the carcinogenesis of synchronous gastric 
carcinomas associated with adenoma and in early human gastric cancer (Fleisher et al 
2001, Bevilacqua et al 2000). 
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In the present study, microstellite instability is an uncommon event and has been 
observed in one (4%) gastric carcinoma at multiple loci only. This case also revealed 
hypermethylation of hMLHl gene promoter by methylation specific PCR (Figure 23), 
suggesting that silencing of hMLHl gene is involved in aetiology of gastric carcinoma. 
However, immunohistochemical study on expression of hMLHl should be performed in 
order to confirm the low expression of hMLHl protein. Recently, Kang et al suggested 
promoter hypermethylation of hMLHl is a one of the main inactivation mechanism in 
gastric carcinoma (Kang et al 2001). Our result appears to be consistent with recent 
studies concerning the correlation between microsatellite instability and 
hypermethylation of mismatch repair gene as it was suggested that defective hMLHl 
gene was usually observed in gastric carcinomas with high level microsatellite instability 
(Hailing et al 1999). Compared to previous studies, lower frequencies of microsatellite 
instability were reported (Dos Santos et al 1996, Rhyu et al 1994, Chong et al 1994). It is 
because compared to the microsatellite markers selected in the present study might not be 
efficient enough for the detection of microsatellite instability. Moreover, small number of 
cases studied might also account for the difference. Other hypermethylated genes 
involved in gastric carcinoma include pi 6, THBSl and TIMP-3 (Kang et al 2001). 
In this study, case 14 showed microsatellite instability is an intestinal type of gastric 
carcinoma. It is in agreement with previous study that the intestinal type gastric cancers 
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Figure 23. Methylation of hMLHl promoter (by MSP). 
Case 14 (tumor) showed hypermethylation of hMLHl gene. 
+ve control = Universial methylated D N A 
H2O = Water 
M=Methylated D N A 
U=Unmethylated D N A 
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VII.5 Correlations 
Correlations between L O H of these two regions and clincopathological parameters (age, 
sex, histological diagnosis, H. pylori infection, stage or metastasis) were also studied. 
However, no significant associations were found. Since the number of samples was 
limited and they tended to be of advanced stage, further studies are necessary to reveal 
correlations between these two regions and the clincopathological features. Nevertheless, 
loss of 6q was observed in both type of gastric carcinoma and in early and advanced 
(stage I to IV) stages. This is consistent with the report of Carvalho et al (Carvalho et al 
1999). Loss of chromosome 6q is a non-random event that occurs in the early stages of 
development of gastric cancer and is associated with the development of both types of 
gastric carcinoma. 
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VIL6 Comparison Between CGH and LOH Results on Chromosome 6 
An overall concordance of 50% was obtained when C G H results compared with L O H 
results (Table 12). Concerning losses of chromosomal material, L O H studies confirmed 
70% of cases detected by CGH. In contrast, C G H studies detected only 10% of losses of 
chromosomal material detected by L O H studies. This discrepancies might be due to the 
fact that C G H only allows the detection of deletion size of at least lOMbp，implying that 
some of the deletion regions observed in L O H studies may be too small to be detected by 
C G H (Bentz et al 1998). Moreover, C G H is a method that allows the detection of loss 
and gains of chromosomal material, but not detection of the loss of alleles, as detected by 
L O H studies (Peters et al 2000). Furthermore, microsatellite markers used in L O H 
studies were not located in the region of losses detected in CGH. Also, when a region of 
gain and normal juxtaposes to a small region of loss, C G H may not detect. Locations 
defined by three different maps (cytogenetic map, genetic and physical map) might also 
account for the discrepancy of locations of deletion region defined. Therefore, 
discrepancies between C G H and L O H studies are to be expected. Finally, uniparental 

















































































































































































































It is the first study on chromosome 6q on gastric intestinal metaplasia. Loss of 
chromosome 6q is probably not involved in the process of progression from normal 
gastric mucosa to intestinal metaplasia. It may occur after the stage of intestinal 
metaplasia. Our results show that deletion of chromosome 6q is a frequent, non-random 
event in gastric carcinoma. As it is observed in gastric carcinoma of all stages (stage I to 
stage IV)，loss of 6q appears to be important in the early development of gastric cancer. 
W e also delineated two distinct deletion regions at 6q 14-21 and 6q27 regions, which 
might contain tumor suppressor genes involved in the gastric carcinogenosis. Putative 
candidate tumor suppressor genes at 6q 14-21 include CCNC, AIMl, SEN6A, while 
SEN6, AF-6, RNASE6PL, PDCD2 and THB2 at 6q 27. Furthermore, microsatellite 
instability on 6q is infrequently detected in this study. Hence, potential mutation of genes 
on chromosome 6q involved in replication repair may not be a frequent event in the 
pathogenesis of gastric carcinoma. 
This study may provide valuable data for the cloning and identification of the candidate 
tumor suppressor genes that are important in this and perhaps other human malignancies. 
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VIL8 Limitations of the Study 
VIL8.1 Limitation of CGH 
C G H detect increases or decreases in D N A copy number, rather than amplifications or 
deletions. In additions, this method does not detect point mutations, amplifications or 
deletions in small regions or translocations. C G H is most likely to find genetic changes 
that involve large enough (> 10-20Mb) region of increases or decreases in the D N A copy 
number or high level (>5-7 fold) increases in a small region (a few hundred kb). 
Therefore, some deletion regions may not be detected. 
VIL 8.2 Limited Information Supply by LOH Analysis 
Although PGR allelotyping is capable of showing losses of genetic materials in tumors, it 
is unsuitable for detection of gene amplifications. To rule out the possibility of gene 
amplification, multiplex PGR should perform to compare the intensity of two locus. 
VIL8.3 Small Sample Size 
Also, small sample size is another limitations in my study. As more cases are included, 
more representative results will come out. Moreover, the follow up information of the 
patients is not available. Therefore, we cannot correlate the loss regions with clinical 
data. Gastric carcinoma samples from low risk population may also be helpful for 
determination of the importance of loss of 6q in the carcinogensis of gastric carcinoma. 
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VII.9 Future Studies 
More micosatellite markers should be included in order to fine map the smallest deletion 
regions identified in this study. Moreover, as C G H is unreliable for telomeric region 
assessment, loss of 6q27 region detected by L O H should be confirmed by Fluorescence 
In Situ Hybridization (FISH) using 6q telomeric probe or specific yac probe. Even though 
some candidate tumor suppressor genes are suggested, future studies on identification of 
more candidate tumor suppressor genes by positional cloning should be carried out. 
Expression, function and mutation of those candidate tumor suppressor genes apparently 
involved in gastric carcinoma development need to be confirmed. Furthermore, 
monochromosome transfer, replacing candidate suppressor genes by transfection, may be 
helpful in determining their importance in tumorgenicity of gastric carcinoma. In order to 
better define the relationship between intestinal metaplasia and gastric carcinoma, more 
cases with intestinal metaplasia and different approach studies should be should be 
included in future studies. For example, overall genetic abnormalities of intestinal 
metaplasia can be analysis by CGH. Furthermore, contamination of normal tissue may 
reduce the frequency of loss detected. Therefore, more sophisticated techniques on 
microdissection for example laser microdissection should be applied in order to get a 
representative sample. 
Application of microarray C G H is another approach. As a result of the use of metaphase 
chromosomes, the resolution of C G H is limited to link copy number changes to genes 
involved. However, in microarry CGH, the substrate is not a normal metaphase spread, 
but an array of D N A fragments (lOObp to lOOkb), and therefore, the precise 
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chromosomal locus of each is known. In this way, by using an array of approximately 
5000 spots, a genome wide analysis for gains and losses at a 1Mb resolution is possible. 
In microarray expression analysis, it is focused on differences in gene expression level 
between normal and abnormal tissue (Snijders et al 2000). Arrays of cDNAs of known 
genes are spotted on to a carrier. Subsequently, labeled R N A cDNA probes synthesized 
from m R N A isolated both from abnormal and normal tissues are co-hybridised onto the 
array. The signal intensities for every spot can be determined, which provides a measure 
of the expression of thousands of genes in a single experiment. This technique not only 
yields information about the expression of individual genes in different tissues, but also 
on the regulation of different genes organized in pathways (Snijders et al 2000). 
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